Brexit delay offers biopharma more time to prepare for a no-deal

Although Europe remains at risk of a drug supply disruption in the event of a no-deal Brexit, Thursday's extension means more time for British biopharma companies to get drug applications approved, and for the U.K. and EU to address supply chain concerns.